// App-Quantinova.ai

4533 : Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).

Researchers

Presenter

  • Tian Zhang

Principal Investigators

  • Janet S. Staats

  • Cliburn Chan

  • Michael Roger Harrison

  • Peter H. O'Donnell

  • Kristen A Batich

  • Tianling Chen

  • Cecile Krejsa

  • Raquel Izumi

  • Daniel J. George

  • Kent J. Weinhold

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • University of Chicago Comprehensive Cancer Center, Chicago, IL

  • ICON Dev Soultions, Palo Alto, CA

  • Acerta Pharma, Redwood City, CA

  • Duke University, Durham, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • B7 homolog 3

  • B-lymphocyte antigen CD20

  • C-C Motif Chemokine Receptor 4

  • C-C Motif Chemokine Receptor 7

  • Cluster of Differentiation 14

  • Cluster of Differentiation 19

  • Cluster of Differentiation 25

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 38

  • Cluster of Differentiation 4

  • Cluster of Differentiation 56

  • Programmed cell death 1 ligand 2

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Cluster of differentiation 8A

  • Protein Tyrosine Phosphatase, Receptor Type C

  • Cytotoxic T-lymphocyte-associated protein 4

  • Fc gamma RIIIa

  • Human Leukocyte Antigen – DR isotype

Drug/Treatment

  • Pembrolizumab

  • ACP-196

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved